Summing up the Meeting of Experts "New Potentialities in Prevention of Hemophilia Complications in Children and Adults", Moscow, August 30, 2010 (Tarasova I. S.)

REFERENCES

1. Nilsson I. M., Berntorp E., Löfqvist T., Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J. Intern. Med. 1992; 232 (1): 25—32.

2. Berntorp E., Astermark J., Björkman S. et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (suppl. 1): 1—4.

3. Manco-Johnson M. J., Abshire T. C., Shapiro A. D. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 2007; 357 (6): 535— 544.

4. Löfqvist T., Nilsson I. M., Berntorp E., Pettersson H. Haemophilia prophylaxis in young patients — a long-term follow-up. J. Intern. Med. 1997; 241 (5): 395—400.

5. Manco-Johnson M. J., Nuss R., Geraghty S. et al. Results of secondary prophylaxis in children with severe hemophilia. Am. J. Hematol. 1994; 47 (2): 113—117.

6. Kreuz W., Escuriola-Ettingshausen C., Funk M. et al. When should prophylactic treatment in patients with haemophilia A and B start? — The German experience. Haemophilia 1998; 4 (4): 413—417.

7. Fischer K., van Hout B. A., van der Bom J. G. et al. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol. 2002; 43 (5): 528—32.

8. Brackmann H. H., Eickhoff H. J., Oldenburg J., Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22 (5): 251—258.

9. Aledort L. M., Haschmeyer R. H., Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J. Intern. Med. 1994; 236 (4): 391—399.

10. Dzinaj T., Funk M., Schmidt H. et al. Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis. Thromb. Haemost. 1996; 76 (4): 630—631.

11. Liesner R. J., Khair K., Hann I. M. The impact of prophylactic treatment on children with severe haemophilia. Br. J. Haematol. 1996; 92 (4): 973—978.

12. Fischer K., Astermark J., van der Bom J. G. et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8 (6): 753—760.

13. Pipe S. W. Recombinant clotting factors. Thromb. Haemost. 2008; 99 (5): 840—850.

14. Gouw S. C., van der Bom J. G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11): 4648—4654.

15. Kurnik K., Bidlingmaier C., Engl W. et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16 (2): 256— 262.

16. Mannucci P. M., Schimpf K., Brettler D. B. et al. Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group. Ann. Intern. Med. 1990; 113 (1): 27—32.

17. Pollmann H. 15 years experience with virus safety of pasteurized factor VIII concentrates in Germany. In: XXII International Congress of the World Federation of Haemophilia, 23—28 June 1996; Haemophilia 1996; 2 (suppl. 1): 24.

18. Ewenstein B. M., Joist J. H., Shapiro A. D. et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42 (2): 190—197.